Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Intern Med J. 2022 Sep;52(9):1609-1623. doi: 10.1111/imj.15533. Epub 2022 Jul 21.


Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.

Keywords: diagnosis; diffuse large B-cell lymphoma; management; prognosis.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Consensus
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / diagnosis
  • Lymphoma, Large B-Cell, Diffuse* / therapy
  • Rituximab / therapeutic use
  • Transplantation, Autologous


  • Rituximab